TumorScan: perfect accuracy

Universal blood test for cancer will soon appear on the market

Svetlana Maslova, Hi-tech+

In the UK, a license has been issued for the industrial production of a diagnostic test for high-sensitivity cancer. It can become the first screening tool for preventive examination.

Scientists from Bradford University (UK) have licensed the technology for the production of TumorScan diagnostic tests for the presence or absence of cancer by the method of the so-called liquid biopsy, that is, by blood analysis.

At the moment, the claimed accuracy of the study is 93%, but the new analyzer can increase the values to the maximum, according to the university's website (‘Universal’ blood test for earlier diagnosis of cancer moves closer to market).

The test is fundamentally different from analogues. It detects the presence of dangerous tumors regardless of the triggers, so it does not look for specific biomarkers or mutations. Scientists have found a way to measure leukocyte DNA damage when exposed to different levels of ultraviolet light intensity. As a result, measurable differences are revealed in cells that are further damaged if a person has cancer.

The use of a more modern Cellfinder system for cell analysis has already increased the effectiveness of the test. The latest study identified patients with oncopathology with 100% accuracy and excluded healthy ones.

The developers believe that such synergy will allow achieving important indicators for the market: obtaining research results within a day, as well as the affordable cost of the test.

If cancer is detected, then immunotherapy is now considered one of the most promising methods of treatment. Scientists from the USA used genetically modified immune cells and created an effective vaccine against cancer with metastases.

Portal "Eternal youth" http://vechnayamolodost.ru